Super response to liraglutide in people with obesity: A case report and literature review.

Sonsoles Gutiérrez Medina, Sonsoles Guadalix, Javier Escalada, Elena Sánchez Campayo

Journal: Endocrinologia, diabetes y nutricion 2024;71(10):447-453

PMID: 39617632

Full Text on Elsevier Science View on PubMed

Abstract

GLP1 receptor agonists (GLP1-RAs) are currently the most widely used pharmacological option to treat obesity. However, considerable heterogeneity in weight loss response has been observed with different anti-obesity drugs and response predictors to these drugs still remain ambiguous. Furthermore, very few published data have been available on cases of high-responders to treatment with GLP1-RAs. In this article, we present the case of a patient with grade 4 obesity (initial body mass index, 50.2kg/m) with associated mechanical and metabolic complications who achieved an initial weight loss of 40% at 1 year with hygienic-dietary measures and drug treatment with liraglutide. We also review the available literature on factors potentially contributing to variations in weight loss with GLP1-RAs in general and liraglutide, in particular.

Address: Clínica Universidad de Navarra, C. del Marquesado de Santa Marta 1, 28027 Madrid, Spain. Electronic address: [email protected].; Clínica Universidad de Navarra, C. del Marquesado de Santa Marta 1, 28027 Madrid, Spain.; Clínica Universidad de Navarra, Av de Pío XII 36, 31008 Pamplona, Navarra, Spain.

DOI: 10.1016/j.endien.2024.11.012

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-AKR1B1-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Anti-Obesity Agents, Hypoglycemic Agents, Liraglutide, Obesity, Weight Loss